ReviewAmerican health & drug benefits2019
Evolution of the Medicare Part D Medication Therapy Management Program from Inception in 2006 to the Present.
Review in American health & drug benefits, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of medication therapy management programs on potentially inappropriate medication use in older adults: A systematic review.Journal of managed care & specialty pharmacy · 2024Pooled it
- Pharmacist-led interventions to improve medication adherence in older adults: A meta-analysis.Journal of the American Geriatrics Society · 2021Pooled it
- Development of a Core Outcome Measurement Set for studies of community pharmacist-led medication reviews in older patients with multimorbidity and polypharmacy.International journal of clinical pharmacy · 2026Article
- Resolving Medication-Related Problems in Older Adults through a Multidisciplinary Approach in Korea's Hospital-Based Polypharmacy Program.Yonsei medical journal · 2026Article
- The association between comprehensive medication review and medication adherence among medicare beneficiaries with chronic obstructive pulmonary disease.Exploratory research in clinical and social pharmacy · 2024Article
- Impact of comprehensive medication reviews on potentially inappropriate medication discontinuation in Medicare beneficiaries.Journal of the American Geriatrics Society · 2024Article
- The Chronic Conditions Care Collaborative (4C Collaborative): A Platform for Improving Diabetes and Heart Disease Outcomes in Rural South Carolina.American journal of lifestyle medicine · 2024Article
- Racial and ethnic disparities related to the Medicare Part D Medication Therapy Management Program.Journal of managed care & specialty pharmacy · 2024Article
- Effects of comprehensive medication review on opioid overuse among medicare beneficiaries.Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain · 2024Article
- An Effectiveness Study of a Primary Care-embedded Clinical Pharmacist-Led Intervention Among Patients With Diabetes and Medicaid Coverage.Journal of pharmacy practice · 2024Article
- Applying the Andersen behavioral model to the medication therapy management program: an approach for improving medication safety in older adults.Frontiers in public health · 2024Article
- Building health plan-pharmacist provider partnerships to optimize medication outcomes.Journal of managed care & specialty pharmacy · 2023Article
- Racial and ethnic disparities in the enrolment of medicare medication therapy management programs.Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain · 2023Article
- It is time for a new comprehensive medication review quality measure.Journal of managed care & specialty pharmacy · 2023Article
- Cost-Effectiveness of Medication Therapy Management Program Across Racial and Ethnic Groups Among Medicare Beneficiaries.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023Article
- Predictors of Receipt of Comprehensive Medication Reviews in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Effects of Medicare comprehensive medication review on racial/ethnic disparities in nonadherence to statin medications among patients with Alzheimer's Disease: an observational analysis.BMC health services research · 2022Observational
- Exploring Racial and Ethnic Disparities in Medication Adherence Among Medicare Comprehensive Medication Review Recipients.Exploratory research in clinical and social pharmacy · 2021Article
- Effects of the Medicare Part D comprehensive medication review on medication adherence among patients with Alzheimer's disease.Current medical research and opinion · 2021Article
- Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Adherence.American health & drug benefits · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2006, the Centers for Medicare & Medicaid Services (CMS) implemented the newly established Medicare Part D program that required plan sponsors to offer a medication therapy management (MTM) program. The MTM program requirements have become more prescriptive over the past decade in the attempt to address low beneficiary enrollment rates, improve the quality of services provided, and address gaps in meeting the needs of enrollees.
objectiveTo describe changes to the requirements for the Medicare Part D MTM program since its inception in 2006 and the impact of these changes to inform future program enhancements.
methodsWe obtained publicly available information extracted from the Medicare Part D MTM program fact sheets for the years 2008 through 2018, in addition to searching indexed literature through PubMed and additional literature through Internet searches. We then categorized the program's requirement changes annually, and described the Part D MTM program characteristics and reported statistics. DISCUSSION: Significant changes to the Part D MTM program requirements occurred in 2010, 2013, and 2016 regarding eligibility criteria, MTM services, and reporting requirements. Thresholds to determine beneficiary eligibility have been lowered. Specific MTM services now include an annual comprehensive medication review, followed by a written summary using the Standardized Format. Quarterly targeted medication reviews are also required. Reporting requirements now include comprehensive medication review completion rates and the number of prescriber interventions, among others. Despite more prescriptive MTM program requirements, the low utilization of the MTM program continues.
conclusionLow beneficiary enrollment rates in the Medicare Part D MTM program led CMS to lower thresholds required for eligibility to expand the beneficiary pool. More prescriptive MTM service requirements enhanced service standardization. Despite these changes, MTM enrollment and comprehensive medication review rates remain low, likely, in part, from a lack of financial incentives. The Enhanced MTM program is a 5-year test model that is providing participating Part D plans regulatory flexibility and financial incentives to design their own MTM programs, to evaluate the impact of different program designs on beneficiary engagement and outcomes.
Indexed as
Identifiers
32015791PMC6979045What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.